Back to results
US 2010/0063046 A1Published application
Tetracyclic imidazole analogs
OwnerJeffrey P. Whitten, Michael Schwaebeinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides tetracyclic imidazole analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing these compounds, and methods of using the same.
Claims26
A compound of formula (1) or (2) or (3),
- wherein each A, V, B, and X that is present is independently selected from H, halo, azido, CN, CF3, CONR1R2, R2, CH2R2, SR2, OR2C(═O)R2, and NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group;
- or
- wherein A and X, or A and V, or X and B may form a carbocyclic ring, heterocyclic ring, aryl or heteroaryl ring, each of which may be optionally substituted with one or two R3 groups and/or may be fused with an additional ring;
- wherein in L-NR1R2, R1 and R2 taken together may form an optionally substituted azacyclic group, or R1 or R2 taken together with at least a portion of L may form an optionally substituted heterocyclic ring;
- each Z is independently CH, CR3 or N;
- each Z1, Z2, Z3, and Z4 is independently C or N, provided no two of them represent adjacent nitrogen atoms;
- T is O, S(O)m or NR4;
- each R1 is H or a C1-10 alkyl or C2-10 alkenyl group that can be substituted with one or more substituents selected from halo, ═O, OR2, NR22, S(O)mR2, COOR2, and CONR22;
- each m is independently 0-2;
- each n is independently 0-4;
- each R2 is independently H or an optionally substituted C1-10 alkyl or optionally substituted C2-10 alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S in place of carbon atoms, and optionally including a carbocyclic or heterocyclic ring;
- or R2 is an optionally substituted carbocyclic, heterocyclic, 6-10 membered aryl or 5-14 membered heteroaryl ring containing one or more N, O or S;
- each R3 is independently an optionally substituted group selected from C1-6 alkyl, C6-10 aryl, and C5-12 heteroaryl, or R3 is selected from halo, nitro, OR′, SR′, SO2R′, NR′2, CN, CF3, COOR′, and CONR′2, wherein each R′ is independently H or C1-6 alkyl and can optionally include one N, O or S in place of a carbon atom, or R3 can be L-NR1R2 or CON(R′)-L-NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group;
- each R4 is H or a C1-10 alkyl or C2-10 alkenyl group that can be substituted with one or more substituents selected from halo, ═O, OR2, NR22, S(O)mR2, COOR2, and CONR22;
- each L is a divalent hydrocarbon linker having up to ten atoms counted along the shortest path between the two open valence, which linker may include one or two heteroatoms and may be substituted by one or more groups selected from halo, ═O, C1-6 alkyl, OR′, SR′, SO2R′, NR′2, CN, CF3, COOR′, and CONR′2, wherein each R′ is independently H or C1-6 alkyl;
- each W represents an optionally substituted aryl or heteroaryl ring, which may be a monocyclic group with 5-6 ring atoms, or may be a 5-6 membered ring that is fused with or bonded to one or more additional aryl, heterocyclic, or heteroaryl rings;
- and
- each R5 is a substituent at any position on W, and is selected from H, halo, CN, CF3, OR2, NR1R2, and C1-6 alkyl and C2-6 alkenyl, each optionally substituted by one or more substituents selected from halo, ═O, OR2, S(O)mR2, and NR1R2, wherein in NR1R2, R1 and R2 can optionally cyclize to form an optionally substituted azacyclic group;
- or R5 can be an inorganic substituent;
- or two adjacent R5 may be linked to form a 5-6 membered substituted or unsubstituted carbocyclic or heterocyclic ring, optionally fused to an additional substituted or unsubstituted carbocyclic or heterocyclic ring;
- or a pharmaceutically acceptable salt thereof.
18 more elements
2-4. (canceled)
The compound of claim 3, wherein T is NR4.
23-26. (canceled)
28-29. (canceled)
(canceled)
Dependencies are inferred from the claim text.